Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study..
Curr Med Res Opin. 25(8), 1931-40.
(2009). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?.
Curr Vasc Pharmacol. 13(3), 368-80.
(2015). Prevalence of vascular disease in metabolic syndrome using three proposed definitions..
Int J Cardiol. 117(2), 204-10.
(2007). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015). Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?)..
Curr Vasc Pharmacol. 12(6), 870-2.
(2014). Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action..
Indian Heart J. 68(5), 596-598.
(2016). Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?.
Curr Pharm Des. 16(34), 3939-847.
(2010). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study..
Curr Med Res Opin. 25(4), 971-80.
(2009). Statins and non-alcoholic steatohepatitis..
J Hepatol. 64(1), 241-2.
(2016). Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy..
Expert Rev Cardiovasc Ther. 13(9), 1059-66.
(2015). Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate..
Nat Rev Endocrinol. 8(3), 133-4.
(2012). Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia..
Am J Cardiol. 101(11), 1679-80.
(2008). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis..
Curr Vasc Pharmacol. 16(2), 104-106.
(2018). Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?.
Curr Vasc Pharmacol. 14(1), 88-97.
(2016). Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?.
Curr Vasc Pharmacol. 14(6), 494-497.
(2016). Diabetes and lipid metabolism..
Hormones (Athens). 17(1), 61-67.
(2018). Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease..
Expert Opin Ther Targets. 17(7), 861-2.
(2013). Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy..
Curr Vasc Pharmacol.
(2014). High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice..
J Diabetes Complications. 30(1), 9-11.
(2016). Should adipokines be considered in the choice of the treatment of obesity-related health problems?.
Curr Drug Targets. 11(1), 122-35.
(2010). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007).